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Abstract
Background—Prostate cancer is the most commonly diagnosed non-skin cancer in men in the 
United States and the second leading cause of cancer-related mortality. African American men 
have substantially increased risk of both being diagnosed and dying from the disease. Recent 
genome-wide genetic association studies have identified a number of common single nucleotide 
genetic polymorphisms (SNPs) that are associated with prostate cancer in men of European 
descent. Only a small number of studies have evaluated the association between these genetic 
variants and prostate cancer in African Americans.
Methods—We used logistic regression models to assess the association between prostate cancer 
in African American men and 24 SNPs from regions previously reported to be associated with 
prostate cancer in men of European descent.
Results—We found nominal evidence (P<0.05) for association between prostate cancer and three 
chromosome 8q24 (rs6983561, rs16901979, and rs7000448) and two 10q11 (rs7904463 and 
rs10740051) SNPs.
Conclusions—We confirm recent reports that 8q24 variants identified to be associated with 
prostate cancer in men of European descent are also associated with prostate cancer in African 
Americans. Our report is the first to find evidence of association between SNPs near MSMB and 
prostate cancer in African Americans. Of note, rs7000448 is in strong linkage disequilibrium with 
rs10761581 in NCOA4, a SNP that has been implicated to be independently associated, with 
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respect to the widely reported SNP rs10993994 in the nearby gene MSMB, with prostate cancer in 
men of European descent.
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Introduction
Prostate cancer is the most common cancer among men in the United States with 192,280 
new cases diagnosed and 27,360 deaths estimated in 2009 [1]. In addition to increasing age, 
ethnicity is one of the most important recognized risk factors for the disease [2]. African 
American men have an 1.6-fold greater chance of being diagnosed with prostate cancer 
compared to European American men and a 2.4-fold greater chance of dying from the 
disease [1,2].
Genome-wide association studies (GWASs) have been successful in identifying a number of 
common single nucleotide genetic polymorphisms (SNPs) that are associated with prostate 
cancer in men of European descent [3–6]. Many of these association findings have been 
replicated successfully across multiple studies of European men with prostate cancer. 
Unfortunately, despite their increased risk for developing the disease, African Americans are 
typically under-represented in genetic association studies of prostate cancer. To date, no 
GWASs for prostate cancer have been completed in African American men. The major 
impediment has been the limited availability of sufficient sample sizes of African American 
prostate cancer cases for individual investigators to have sufficient power to discover novel 
common genetic variants associated with prostate cancer in this population. Several recent 
replication-based studies for loci identified in European American prostate cancer GWASs 
have been conducted in cohorts and case control studies of African American men [7–9]. 
The results from these replication studies have been mixed with only chromosome 8q24 
consistently showing some evidence of association with prostate cancer. The difficulty in 
replicating previous findings from European populations can be attributed to different allele 
frequencies and linkage disequilibrium patterns in men of African and European descent and 
the modest sample sizes used in the replication studies. We describe association results for 
24 SNPs, from regions previously identified to be associated with prostate cancer, based on a 
population-based sample of 127 unrelated African American prostate cancer cases and 345 
unrelated disease-free controls. We show nominal evidence (P < 0.05) for association 
between prostate cancer and several 8q24 (rs6983561, rs16901979, and rs7000448) and 
10q11 (rs7904463 and rs10740051) SNPs.
Materials and Methods
The Flint Men's Health Study (FMHS)
In 1996, a probability sample of African-American men was selected from households 
located in Genesee County, Michigan to participate in a study of prostate cancer [10,11]. 
Seven hundred thirty eligible subjects were provided a detailed in-home interview and an 
option to participate in a comprehensive urologic examination (digital rectal exam (DRE), 
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transrectal ultrasound (TRUS), and a screening serum PSA measurement). Prostate biopsy 
was recommended in individuals with an elevated PSA (4.0 ng/ml) or suspicious DRE. 
Three hundred seventy-nine of the 730 men who completed the interview participated in the 
clinical examination component of the study. After exclusion of men who were determined 
to be biopsy positive for prostate cancer at baseline and/or who subsequently developed 
prostate cancer after baseline (included in the present analyses as cases), a sufficient DNA 
sample was available for genotyping on 345 of the remaining controls.
Prostate cancer case recruitment from the same community was initiated in 1999. Eligible 
men include those who were between the ages of 40–79 at time of prostate cancer diagnosis 
(between 1995 and 2002). Cases completed a detailed epidemiologic interview and provided 
a blood sample. Diagnosis of prostate cancer was confirmed by review of pathology reports 
or medical records, and age at diagnosis calculated from the date of the first biopsy positive 
for prostate cancer.
A total of 136 cases were ultimately recruited to participate in the study. A sufficient DNA 
sample was available for genotyping on 127 cases. Informed consent was obtained from all 
study participants and the research protocol was approved by the University of Michigan 
Institutional Review Board. For both cases and controls, genomic DNA was isolated from 
whole blood using the Puregene DNA Purification Kit (Gentra Systems, Inc., Minneapolis, 
MN).
Genotyping Methods
We genotyped 24 SNPs, in 127 FMHS cases and 345 FMHS controls. Genomic DNA was 
isolated from whole blood using the Puregene kit (Gentra Systems, Inc.). The 24 SNPs were 
genotyped using Taqman SNP Genotyping Assays (Applied Biosystems, Foster City, CA). 
Briefly, these assays consisted of a 40× mix of PCR primers and dye-labeled TaqMan MGB 
probes that were designed to interrogate a specific SNP within a given sequence. PCR 
reactions were conducted in a 384-well plate format, with 2.0 μl genomic DNA (5 ng/μl), 
0.125 μl 40× SNP Genotyping Assay Mix, and 2.5 μl Taqman Genotyping PCR Mastermix 
(Applied Biosystems) for a 5 μl total volume reaction. All assays were optimized to use a 
universal thermal cycling protocol with an initial hold at 958° C for 10 min, followed by 40 
cycles of denaturation at 928° C for 15 sec, and a combined annealing extension step at 608° 
C for 1 min. Allelic discrimination was carried out using the ABI PRISM 7900 HTSequence 
Detection System and the SDS version 2.1 software (Applied Biosystems). Approximately 
5% of the samples were duplicated on this platform for verification purposes. No 
discrepancies were observed. Results for one SNP, rs1447295 at 8q24, were reported 
previously [12].
Statistical Analyses
For each SNP, the observed genotype distribution was tested for consistency with Hardy–
Weinberg equilibrium expected proportions using Pearson's chi-square test. Lewontin's D′ 
statistic [13] and the squared correlation statistic R2 were used to estimate the degree of 
linkage disequilibrium and correlation between all possible pair-wise combinations of SNPs 
in the same chromosomal region using the computer software Haploview [14]. Estimated 
Wang et al. Page 3













proportion of West African ancestry for each study participant was obtained using the 
statistical software Structure [15] as described previously [12].
Unconditional single-variable and multivariable logistic regression models were used to test 
whether individual SNP genotypes were associated with prostate cancer using likelihood 
ratio tests implemented in SAS (SAS version 9.1, Cary NC). Specifically, we conducted a 1 
degree-of-freedom test assuming a multiplicative (or log-additive) genetic model. Genotype 
was scored as the number of copies of the allele previously described as the risk allele in 
prostate cancer studies of men of European descent. In addition to unadjusted logistic 
models, covariate-adjusted models were also analyzed including age and the estimated 
proportion of West African ancestry. Finally, for chromosomal regions that contained at least 
1 nominally significant SNP result (P < 0.05), additional analyses were performed: a joint 
analysis of SNPs in the proximity of the associated SNP to assess the cumulative evidence of 
association in the region and multivariable logistic regression analyses that included the 
most strongly associated SNP as a covariate to assess whether there was evidence for 
multiple independently associated SNPs in the region.
Results
The sample consisted of 472 (127 prostate cancer cases, 345 disease-free controls) African-
American subjects with both genotype and phenotype data. Median age overall was 58 years 
(interquartile range = 50–67) with cases being older than controls (cases median age = 62 
years, interquartile range = 55-69.5; controls median age = 55 years, interquartile range = 
49–69; P < 10-7). 19.7% of cases and 20.2% of controls reported a family history of prostate 
cancer in a first degree relative. There was no statistical difference in mean percent African 
descent between cases (70.3%) and controls (70.9%). Characteristics for the 127 prostate 
cancer cases are presented in Table I.
All 24 SNPs had observed genotype frequencies consistent with Hardy–Weinberg 
equilibrium expected proportions (P > 0.001) in study controls. Nominal evidence (two-
sided P < 0.05) for association between prostate cancer and genotype was observed for 5 
SNPs (rs6983561, rs16901979, and rs7000448 at 8q24; rs7904463 and rs10740051 at 
10q11) using unadjusted logistic regression models (Table II). Results were similar for 
multivariable models that included covariate adjustment for age and estimated proportion of 
West African ancestry (data not shown). Four SNPs that have been previously reported to be 
associated with prostate cancer (exception rs10740051) had direction of effects that were 
consistent with previous reports. Rs10740051 had a higher frequency of the minor allele in 
controls, which appears to contradict a previous report by Chang et al. [16] that reported 
results based on imputed genotype data for this SNP in an European case–control sample 
(see the Discussion Section). Estimates of the linkage disequilibrium measures D′ and R2 for 
SNPs at 8q24 and 10q11 are presented in Table III.
Multiple-SNP models for 8q24-associated SNPs suggested that the observed single-SNP 
associations between rs6983561 and rs16901979 and prostate cancer represent the same 
association signal. When modeling rs16901979 jointly with rs6983561, there was overall 
evidence for an association between the two SNPs and prostate cancer (P = 0.0079 for the 2 
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degree-of-freedom (df) test), but neither SNP was individually associated with prostate 
cancer and their associated odds ratios attenuated considerably compared to when the SNPs 
were modeled individually (data not shown). In the two-SNP model that included 
rs16901979 and rs7000448, there was evidence for an overall association (P = 0.0036 for the 
2 df test) between these two SNPs and prostate cancer, rs16901979 remained significantly 
associated with prostate cancer (P = 0.0081; OR = 1.53), but rs7000448 but was no longer 
individually significantly associated with prostate cancer (P = 0.14; OR = 1.30).
Multiple-SNP models for SNPs at 10q11 near MSMB provided marginal evidence for 
multiple independently associated SNPs in the region. We performed two (rs7904463 and 
rs1074005) and three (addition of rs10993994) SNP logistic regression models in the region. 
The overall evidence for an association remained similar to when rs1074005 was analyzed 
alone (Table II) for the two (P = 0.0070 for the 2 df test) and three (P = 0.0087 for the 3 df 
test) SNP models. In both the two and three SNP models, rs1074005 remained nominally 
significantly associated with prostate cancer (P = 0.027 in both models) with only slight 
attenuation of the SNP's associated odds ratios (OR = 0.54 in both models) compared to the 
observed odds ratio when the SNP was analyzed alone (OR = 0.51). In the two and three 
SNP models, statistical significance and associated odds ratios for rs7904463 decreased 
modestly (P = 0.069 and OR = 1.34 for the 2 SNP model; P = 0.054 and OR =1.37 for the 
three SNP model). The widely reported rs10993994 was not associated with prostate cancer 
in the three SNP model (P = 0.21, OR = 1.23), though the direction and size of the effect 
were similar to previous prostate cancer association studies in European Americans.
Discussion
We describe results for a prostate cancer association study from a community-based sample 
of African American men on 24 SNPs found in regions previously reported to be associated 
with prostate cancer in men of European descent. We found nominal evidence for an 
association between prostate cancer and SNPs at 8q24 (rs6983561, rs16901979, and 
rs7000448) and 10q11 (rs7904463 and rs10740051) near MSMB. Our results at 8q24 
replicate findings from other African American prostate cancer association studies that have 
found evidence for associated SNPs in the region [7,9]. The signals for the two most 
strongly associated SNPs at 8q24, namely rs6983561 (8q24 region 2) and rs16901979 (8q24 
region 2), were not independent given the strong LD between the two SNPs (Table III) and 
the strongly attenuated odds ratios for each SNP when including both in the same model 
(data not shown). The nominal evidence for association at rs7000448 (8q24 region 3) 
disappeared when including rs16901979 in the model. However, the associated odds ratio 
for rs7000448 remained relatively high (OR = 1.30 in the two SNP model compared to OR = 
1.41 when rs7000448 was analyzed separately) after adjustment for rs16901979, suggesting 
that there is more than one independent risk factor in the region and that we had low power 
to detect one risk factor in the presence of the other.
Our study is the first study to report an association between SNPs at (rs7904463) and near 
(rs10740051) MSMB and prostate cancer in African American men. Interestingly, our most 
strongly associated SNP at 10q11, rs10740051, is in a neighboring gene NCOA4. This SNP 
is in LD with rs10761581 [estimated R2/D′ in HapMap CEU = 0.58/1.00, YRI = 0.15/1.00] 
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(www.hapmap.org), which was suggested by Chang et al. [16] to be a second independent 
locus near MSMB to be associated with prostate cancer. NCOA4 [otherwise known as 
ARA70] is an interesting candidate gene because it is known to increase androgen receptor 
transcriptional activity in human prostate cancer cells [17]. Chang et al. evaluated imputed 
genotype data for rs10740051 and found nominal evidence of association with prostate 
cancer (P = 0.036). Consistent with Chang et al., our results at rs10740051 appear to be 
independent of results for the widely reported MSMB SNP rs10993994, which was not 
significant in our study despite having an estimated odds ratio that was identical in direction 
and similar in magnitude to previous reports in European Americans. The direction of effect 
for rs10740051 appears to differ between our findings and those of Chang et al., with the 
minor allele in our study being less frequent in African American cases. The frequency of 
the minor allele for rs10740051 was also lower in our African American controls (0.13) than 
in the European American controls used by Chang et al. (estimated based on imputation to 
be 0.24 using CEU HapMap samples as the reference sample; frequency. 0.36 in CEU 
samples). The quality score of the imputed genotype data was not reported for this SNP in 
Chang et al. It remains a question whether our result at rs10740051 represents corroboration 
of a second independent locus near MSMB or a false positive finding.
A major limitation with prostate cancer studies on African Americans has been small sample 
sizes for individual studies. One obvious ramification of limited sample size is the impact on 
statistical power to detect significant genetic effects when present. Our study is not immune 
to this limitation and we note in most instances that our effect size estimates, presented as 
odds ratios and their associated 95% confidence intervals, were not significantly different 
than those from previous prostate cancer association reports based on European ancestry 
populations. None of our top results would meet formal statistical significance if a strict 
Bonferroni significance threshold were applied to our findings using two-sided hypothesis 
tests. We note however that we have identified two independent regions containing SNPs 
with evidence of association (P< 0.01). Further, we note that results at 8q24 for two SNPs 
(rs6983561 and rs16901979) would be statistically significant after Bonferroni correction 
using one-sided hypothesis tests that factored in the consistent direction of effects observed 
for these SNPs in this report with those from previous reports. Future larger meta analyses 
will be necessary to definitively assess the association of common genetic variants with 
prostate cancer in African American men. Given the relatively small number of African 
American prostate cancer cases available to genetic researchers, the FMHS will continue to 
be a valuable resource for identifying and validating genetic variants associated with prostate 
cancer in this understudied population.
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Table I
Characteristics of men with prostate cancer (n=127)
Characteristic median [interquartile range] or n (%)
Age at Diagnosis (years) 62 [55-69.5]
Serum prostate-specific antigen at diagnosis (ng/mL) 6.3 [4.3-11.925]
Surgery 69 (54.3)
Family Historya 25 (19.7)
Stageb
 Localized 97 (78.2)
 Locally Advanced 21 (16.9)
 Metastatic 6 (4.8)
Gleason
 5-6 35 (28.7)
 7 74 (60.7)
 8-10 13 (10.7)
Clinically aggressive prostate cancerc 45 (35.4)
a
Family history defined as prostate cancer diagnosed in a first-degree relative.
b
Localized=T1 or T2, N0, and M0, or PSA>20ng/ml if treated w/o surgery Locally Advanced=T3 or T4, N0, and M0, or PSA<20ng/ml or 
>100ng/ml Metastatic=N1, or M1, or PSA>100ng/ml if treated w/o surgery.
c
Gleason>7, or T3b or T4, Gleason=7 and post surgical margin or PSA>10ng/ml, or PSA>15ng/ml, or M1.
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